Canandaigua National Bank & Trust Co. Buys Shares of 6,887 Stryker Corporation $SYK

Canandaigua National Bank & Trust Co. bought a new position in Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel reports. The fund bought 6,887 shares of the medical technology company’s stock, valued at approximately $2,168,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Sankala Group LLC acquired a new position in Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG bought a new stake in Stryker in the fourth quarter worth approximately $28,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on SYK. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Citigroup restated an “outperform” rating on shares of Stryker in a research note on Monday. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

NYSE:SYK opened at $337.41 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a 50-day moving average of $318.85 and a 200-day moving average of $334.29. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a market capitalization of $129.42 billion, a price-to-earnings ratio of 34.97, a PEG ratio of 2.14 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.